Research presented at the American Heart Association's Scientific Sessions 2025 suggests that obese adults with atrial fibrillation may experience fewer AFib episodes after ablation when taking the diabetes medication metformin. The study found that metformin users were more likely to remain free of AFib episodes for a year, indicating promising results in reducing irregular heart rhythms. Further studies may investigate metformin's effectiveness compared to other diabetes medications in treating AFib in individuals with obesity.